| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/31/2002 | WO2001068120A3 Uses of bombesin receptor 3 |
| 01/31/2002 | WO2001064870A3 Mutated cyclin g1 protein |
| 01/31/2002 | WO2001062940A3 New phosphodiesterase type 7b |
| 01/31/2002 | WO2001062775A3 Novel antiarrhythmic peptides |
| 01/31/2002 | WO2001062341A3 Combination product for the treatment of obesity |
| 01/31/2002 | WO2001060348A3 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 01/31/2002 | WO2001054677A3 Ace inhibitor-vasopressin antagonist combinations |
| 01/31/2002 | WO2001044284A3 Chimeric natriuretic peptides |
| 01/31/2002 | WO2001038503A3 Novel human protein kinases and protein kinase-like enzymes |
| 01/31/2002 | WO2001036605A3 2786, a human aminopeptidase |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | WO2000059941A9 Purposeful movement of human migratory cells away from an agent source |
| 01/31/2002 | US20020013374 Administering compound effective to inhibit binding of an amyloid beta peptide with alpha-7 nicotinic acetylcholine receptors |
| 01/31/2002 | US20020013358 Indole derivatives |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013356 New polycyclic indanylimidazoles with alpha2 adrenergic activity |
| 01/31/2002 | US20020013354 p38 map kinase inhibitors |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020013335 Method of treating cardiovascular disease |
| 01/31/2002 | US20020013334 HMG-CoA reductase inhibitors and method |
| 01/31/2002 | US20020013329 For therapy of pain, migraine, depression, anxiety, schizophrenia, Parkinson's disease, stroke, and in therapy of neuropathies including postherpetic neuralgia, central pain from spinal cord injury, and phantom limb pain |
| 01/31/2002 | US20020013321 Used as ligands for opioid receptors, for therapy of neurological and gastrointestinal disorders |
| 01/31/2002 | US20020013313 4,5-dihydro-1,3-dithia-4-aza-acenaphthylene-3,3-dioxide compounds for example; treating ischemia, Alzheimer's disease, schizophrenia; alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) |
| 01/31/2002 | US20020013308 Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier |
| 01/31/2002 | US20020013304 As needed rather than involving chronic pharmacotherapy; formulations and kits |
| 01/31/2002 | US20020013297 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/31/2002 | US20020013291 Reperfusion injury; 2-Deoxy-6-O-(2-deoxy-4-O-phosphono-3-O-(3-tetradecanoyloxytetradecanoyl)-2 -(3-octadecanoyloxy-tetradecanoylamino)-beta-D-glucopyranosyl)-2-(3 -hexadecanoyloxytetradecanoylamino)-D-glucopyranose |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013261 Contacting a localized area of tissue with the polymer; treating ischemia |
| 01/31/2002 | US20020013257 Use of ligands to GABAB receptors |
| 01/31/2002 | US20020013256 Novel inhibitors of formation of advanced glycation endproducts (AGES) |
| 01/31/2002 | US20020012906 Method for kidney disease treatment by drug intervention |
| 01/31/2002 | US20020012715 Protecting cell from damage caused by free radicals by administering lipophilic antioxidant comprising vitamin E, beta carotene, extract of Lycopersicum esculentum, hydrophilic antioxidant comprising vitamin c, extract of vitis vinifera |
| 01/31/2002 | US20020012713 Water-soluble complex of an extract of ginkgo biloba, process for the preparation thereof and composition comprising the same |
| 01/31/2002 | US20020012708 For preparation of medicaments for treatment of organ and tissue damages caused by radiation, infections, and chemically, especially of O-MALT system of small intestine, bone marrow, spleen, lymph nodes, liver |
| 01/31/2002 | US20020012664 Combining agent to be tested, antibody or antigen-binding fragment which binds to amino terminal domain of mammalian CC-chemokine receptor 2, mammalian CC-chemokine receptor 2 or ligand-binding variant, measuring binding |
| 01/31/2002 | DE19881732C1 New phosphodiesterase inhibiting 2-phenyl-imidazotriazinone derivatives useful for treating e.g. cardiovascular, cerebrovascular and/or urogenital diseases |
| 01/31/2002 | DE10035352A1 Verfahren zur Behandlung von instabiler Angina pectoris A method for the treatment of unstable angina |
| 01/31/2002 | DE10035144A1 Cyclische Aminosäurederivate Cyclic amino acid derivatives |
| 01/31/2002 | DE10034802A1 Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren Stable salts of O-acetylsalicylic acid with basic amino acids |
| 01/31/2002 | DE10034801A1 Substituierte Amidoalkyl-uracile und ihre Verwendung Substituted amidoalkyl uracils and their use |
| 01/31/2002 | DE10033855A1 Transdermal therapeutic system for long-term treatment of hypertension, containing dicarboxylic acid angiotensin converting enzyme inhibitor converted into salt or ester derivative to improve stability |
| 01/31/2002 | CA2429502A1 Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue |
| 01/31/2002 | CA2417127A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | CA2416870A1 Potassium channel inhibitors |
| 01/31/2002 | CA2416865A1 Potassium channel inhibitors |
| 01/31/2002 | CA2416751A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | CA2416750A1 Compounds having mif antagonist activity |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416544A1 Mu-conopeptides |
| 01/31/2002 | CA2416538A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/31/2002 | CA2416447A1 Novel compounds and their use as glycine transport inhibitors |
| 01/31/2002 | CA2416414A1 Human kinases |
| 01/31/2002 | CA2416358A1 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type i interferons |
| 01/31/2002 | CA2415742A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | CA2415740A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | CA2415585A1 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | CA2415362A1 Method for treating fibrotic diseases or other indications |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2415054A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | CA2415046A1 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2410562A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/30/2002 | EP1176146A1 Carbamoyl tetrahydropyridine derivatives |
| 01/30/2002 | EP1176145A1 Novel guanidino derivatives as inhibitors of cell adhesion |
| 01/30/2002 | EP1176134A1 Ligands of nuclear receptors ppar's |
| 01/30/2002 | EP1175902A1 Use of CS-866 (olmesartan) in the manufacture of a medicament for treating arteriosclerosis |
| 01/30/2002 | EP1175900A2 Use of growth hormone secretagogues for improvement of fucnctional health status |
| 01/30/2002 | EP1175513A1 MinK-RELATED GENES, FORMATION OF POTASSIUM CHANNELS AND ASSOCIATION WITH CARDIAC ARRHYTHMIA |
| 01/30/2002 | EP1175503A1 49 human secreted proteins |
| 01/30/2002 | EP1175497A2 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| 01/30/2002 | EP1175490A2 Tyrosine kinase substrate (tks) proteins |
| 01/30/2002 | EP1175446A1 Human antibodies that bind human il-12 and methods for producing |
| 01/30/2002 | EP1175442A2 Osteopontin-derived chemotactic and inhibitory agents and uses therefor |
| 01/30/2002 | EP1175440A1 48 human secreted proteins |
| 01/30/2002 | EP1175434A2 Eplerenone crystalline form |
| 01/30/2002 | EP1175432A1 Processes for the synthesis of oligomers using phusphoramidite compositions |
| 01/30/2002 | EP1175421A1 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
| 01/30/2002 | EP1175420A2 Process for preparing n6-substituted deaza-adenosine derivatives |
| 01/30/2002 | EP1175417A1 Substituted benzolactam compounds |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 01/30/2002 | EP1175409A1 Pyrimidinones derivatives for the treatment of atherosclerosis |
| 01/30/2002 | EP1175408A1 Pyrimidinone compounds |
| 01/30/2002 | EP1175405A1 LACTAM INHIBITORS OF FXa AND METHOD |
| 01/30/2002 | EP1175400A1 Renin inhibitors |
| 01/30/2002 | EP1175246A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
| 01/30/2002 | EP1175235A1 Modified protein matrices |
| 01/30/2002 | EP1175225A2 Elastin-based compositions |
| 01/30/2002 | EP1175214A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 01/30/2002 | EP1175213A2 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 01/30/2002 | EP1175210A1 Increasing cerebral bioavailability of drugs |
| 01/30/2002 | EP1175157A1 Low molecular weight polymannuronate |
| 01/30/2002 | EP0904284B1 6-substituted amino-4-oxa-1-azabicyclo[3.2.0]heptan-7-one derivatives as cysteine protease inhibitors |
| 01/30/2002 | EP0888373A4 Smooth muscle cell lim protein |
| 01/30/2002 | EP0863876B1 Quinoline derivatives containing a diol as leukotriene antagonists |
| 01/30/2002 | EP0744946B1 Compositions containing micronized nebivolol |
| 01/30/2002 | EP0668913B1 Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
| 01/30/2002 | CN1333785A Interferon-beta fusion proteins and uses |
| 01/30/2002 | CN1333784A Benzylmaltosides as inhibitors of smooth muscle cell proliferation |